- NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF
-
The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic di
- -
-
Page/Page column 38; 40
(2018/04/21)
-
- TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
-
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.
- -
-
Paragraph 0236; 0239
(2017/01/23)
-
- Aurora Kinase Modulators and Method of Use
-
The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
- -
-
Paragraph 0482
(2014/11/27)
-
- FUROPYRIDINE DERIVATIVES
-
Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus
- -
-
Page/Page column 73
(2013/09/12)
-
- FURO [3, 2 - B] - AND THIENO [3, 2 - B] PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS
-
Compounds of the formula (I) in which R1, R2 and X have the meanings indicated in Claim 1, are inhibitors of TBK1 and ΙΚΚε and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.
- -
-
Page/Page column 57
(2013/08/28)
-
- FUROPYRIDINE DERIVATIVES
-
Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of rheumatoid arthritis and / or systemic lupus.
- -
-
Page/Page column 69
(2012/03/26)
-